Anglo-Swedish drugs giant AstraZeneca expects revenue from its Covid-19 medicines to fall by a fifth this year as demand wanes for its life-saving vaccine.
The business has reiterated that it expected sales of Vaxzevria – more commonly known as the Oxford/AstraZeneca vaccine – will decline later in 2022.
